Amazing! Merck and eljian intend to acquire Biogen

Source: nai500 2016-08-04 according to the Wall Street Journal, citing people familiar with the matter, the US biotech giant Biogen has received the acquisition interest of Merck, Elgin and other pharmaceutical companies, and the medical industry is expected to usher in a huge M & a deal On Tuesday, Biogen shares closed up 9.4 percent at $330.11 People familiar with the matter said that Merck and eljian respectively explored Biogen's views on the possibility of acquisition People familiar with the matter said the communication was informal and early, and that a deal might not be reached in the end because Biogen might not be interested in it In Tuesday afternoon trading, Biogen's market value reached $68 billion It is not clear whether other large pharmaceutical companies are also interested in acquiring the biotech company Whether or not a deal is struck, the interest in Biogen reflects the desire of large pharmaceutical companies for new sources of growth Over the years, the product pipeline of large pharmaceutical enterprises has been reduced, and the approval of new drugs has ended Because of the scale, adding a new heavyweight drug is not enough to boost the growth, especially because drug companies are still facing pricing pressure Merck's market value is US $162 billion, and Elgin's market value is US $101 billion Biogen achieved $10.8 billion in sales last year, up 11% Headquartered in Massachusetts, the company dominates the lucrative market for multiple sclerosis drugs At present, the market value of this drug is close to 20 billion USD / year In 2013, tecfidera, a multiple sclerosis drug of Biogen, was approved for marketing Since the beginning of the year, the share price of Biogen has doubled Biogen's share price has fallen sharply from a high of nearly $500 at the beginning of last year, driven by concerns about the company's growth prospects As Roche and other pharmaceutical companies develop competitive drugs, sales of tecfidera slow down Perhaps it was the fall in Biogen's share price that made potential bidders think it might be willing to accept the offer